首页> 外国专利> A 150 KDA TGF-BETA 1 ACCESSORY RECEPTOR ACTING AS A NEGATIVE MODULATOR OF TGF-BETA SIGNALING

A 150 KDA TGF-BETA 1 ACCESSORY RECEPTOR ACTING AS A NEGATIVE MODULATOR OF TGF-BETA SIGNALING

机译:一个150 KDA TGF-BETA 1辅助接收器,用作TGF-BETA信号的负调制器

摘要

The present invention relates to a TGF- beta 1 binding protein called r150. This protein has a GPI-anchor contained in r150 itself and not on a tightly associated protein and that it binds TGF- beta 1 with an affinity comparable to those of the signaling receptors. Furthermore, the released (soluble) form of this protein binds TGF- beta 1 independent of the types I and II receptors. Also, the soluble form inhibits the binding of TGF- beta to its receptor. In addition, evidence that r150 is released from the cell surface by an endogenous phospholipase C is provided. Also, the creation of a mutant human keratinocyte cell line with a defect in GPI synthesis which displays reduced expression of r150 is described. Our results using these mutant keratinocytes suggest that the membrane anchored form of r150 is a negative modulator of TGF-beta responses. These findings, taken together with the observation that r150 forms a heteromeric complex with the signaling receptors, suggest that this accessory receptor in either its membrane anchored or soluble form may antagonize TGF- beta responses in human keratinocytes. Experiments with mutants confirmed that TGF beta 1 activity can be modulated when the expression of the accessory receptor r150 is silenced. The complete nucleic acid and deduced amino acid sequences are now provided. The r150 cloned nucleic acid was used to study overexpression of r150. When r150 gene is overexpressed, TGF beta responses are increased. r150 and its derivatives or precursors (fragments, variants and nucleic acids encoding the same) will find a broad clinical utility, knowing that TGF beta 1 is an important cytokine.
机译:本发明涉及一种称为r150的TGF-β1结合蛋白。该蛋白具有包含在r150本身而不是紧密结合的蛋白上的GPI锚,并且它以与信号转导受体相当的亲和力结合TGF-beta 1。此外,该蛋白的释放(可溶)形式与TGF-β1结合,而与I和II型受体无关。同样,可溶形式抑制TGF-β与其受体的结合。另外,提供了r150被内源性磷脂酶C从细胞表面释放的证据。而且,描述了在GPI合成中具有缺陷的人角质形成细胞突变体的产生,其显示r150的表达降低。我们使用这些突变型角质形成细胞的结果表明,r150的膜锚定形式是TGF-β反应的负调节剂。这些发现与r150与信号转导受体形成异源复合物的观察结果相结合,表明该辅助受体以其膜锚定或可溶性形式可能拮抗人角质形成细胞中的TGF-β反应。突变体实验证实,当辅助受体r150的表达沉默时,TGFβ1的活性可以被调节。现在提供完整的核酸和推导的氨基酸序列。 r150克隆的核酸用于研究r150的过表达。当r150基因过表达时,TGFβ反应增加。 r150及其衍生物或前体(片段,变体和编码它们的核酸)知道TGF beta 1是重要的细胞因子,将在临床上得到广泛应用。

著录项

  • 公开/公告号WO02085942A3

    专利类型

  • 公开/公告日2003-10-09

    原文格式PDF

  • 申请/专利权人 MCGILL UNIVERSITY;PHILIP ANIE;TAM BETTY;

    申请/专利号WO2002CA00560

  • 发明设计人 TAM BETTY;PHILIP ANIE;

    申请日2002-04-24

  • 分类号C12N5/10;A61K38/17;C07K14/715;

  • 国家 WO

  • 入库时间 2022-08-21 23:55:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号